Multiple Sclerosis | Emerging Therapies | Zinbryta (daclizumab) | US | Wave 1 | 2016
Multiple Sclerosis | Emerging Therapies | Zinbryta | US is a three-wave series that tracks the introduction of Zinbryta for the treatment of multiple sclerosis (MS). The series is based on primary research data collected at one, six, and twelve months post-commercial launch with U.S. neurologists. Along with awareness of, sources of familiarity with, and perceptions related to Zinbryta, the research assesses trial, adoption, and usage, including anticipated future trends, of Zinbryta. We also explore Biogen/AbbVie’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched MS agents.
Questions answered:
- What is the awareness of, familiarity with, and perceptions related to Zinbryta among U.S. neurologists?
- Among prescribers, for which patients are they prescribing Zinbryta, what are the reasons for prescribing, and how satisfied are they with Zinbryta?
- What promotional messages and activities are Biogen/AbbVie employing in support of the Zinbryta launch?
- How do prescribers and nonprescribers compare across key metrics?
- How is the trial and adoption of Zinbryta tracking compared to other recent product launches in the MS market?
Scope:
Markets covered: United States.
Primary research: 75 neurologists surveyed for Waves 1 and 2, 100 neurologists surveyed for Wave 3; 10 qualitative interviews per wave with a subset of survey respondents.
Indication coverage: Relapsing-remitting MS.
